Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction
- PMID: 24293121
- PMCID: PMC4282773
- DOI: 10.1007/s11682-013-9272-x
Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction
Abstract
Alzheimer's disease (AD) is an increasingly prevalent, fatal neurodegenerative disease that has proven resistant, thus far, to all attempts to prevent it, forestall it, or slow its progression. The ε4 allele of the Apolipoprotein E gene (APOE4) is a potent genetic risk factor for sporadic and late-onset familial AD. While the link between APOE4 and AD is strong, many expected effects, like increasing the risk of conversion from MCI to AD, have not been widely replicable. One critical, and commonly overlooked, feature of the APOE4 link to AD is that several lines of evidence suggest it is far more pronounced in women than in men. Here we review previous literature on the APOE4 by gender interaction with a particular focus on imaging-related studies.
Figures
Similar articles
-
HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.Mol Psychiatry. 2015 Jul;20(7):867-73. doi: 10.1038/mp.2014.81. Epub 2014 Jul 15. Mol Psychiatry. 2015. PMID: 25023145 Free PMC article.
-
APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease.Alzheimers Dement. 2014 Nov;10(6):861-8. doi: 10.1016/j.jalz.2014.06.015. Epub 2014 Sep 10. Alzheimers Dement. 2014. PMID: 25217293 Review.
-
ApoE4 May be a Promising Target for Treatment of Coronary Heart Disease and Alzheimer's Disease.Curr Drug Targets. 2018;19(9):1038-1044. doi: 10.2174/1389450119666180406112050. Curr Drug Targets. 2018. PMID: 29623835 Review.
-
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration.Mol Neurodegener. 2020 Oct 8;15(1):57. doi: 10.1186/s13024-020-00407-2. Mol Neurodegener. 2020. PMID: 33032659 Free PMC article.
-
Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.J Neurosci. 2019 Sep 11;39(37):7408-7427. doi: 10.1523/JNEUROSCI.2994-18.2019. Epub 2019 Jul 22. J Neurosci. 2019. PMID: 31331998 Free PMC article.
Cited by
-
Alzheimer's disease as a women's health challenge: a call for action on integrative precision medicine approaches.NPJ Womens Health. 2024;2(1):17. doi: 10.1038/s44294-024-00021-3. Epub 2024 May 20. NPJ Womens Health. 2024. PMID: 38778871 Free PMC article. Review.
-
2024 Alzheimer's disease facts and figures.Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30. Alzheimers Dement. 2024. PMID: 38689398 Free PMC article.
-
A case for seeking sex-specific treatments in Alzheimer's disease.Front Aging Neurosci. 2024 Feb 13;16:1346621. doi: 10.3389/fnagi.2024.1346621. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38414633 Free PMC article. Review.
-
Mind the Gap: Unraveling the Intricate Dance Between Alzheimer's Disease and Related Dementias and Bone Health.Curr Osteoporos Rep. 2024 Feb;22(1):165-176. doi: 10.1007/s11914-023-00847-x. Epub 2024 Jan 29. Curr Osteoporos Rep. 2024. PMID: 38285083 Free PMC article. Review.
-
A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice.Alzheimers Res Ther. 2023 Oct 19;15(1):181. doi: 10.1186/s13195-023-01330-6. Alzheimers Res Ther. 2023. PMID: 37858252 Free PMC article.
References
-
- Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–279. doi: 10.1016/j.jalz.2011.03.008. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical